Lunit Inc. announced the presentation of 9 studies at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, to be held in Madrid, Spain, from October 20-24. During this year's congress, Lunit plans to highlight the predictive value and analytical power of its Lunit SCOPE suite, offering valuable insights for understanding the tumor microenvironment, predicting treatment responses, and accurately assessing HER2 scores, in various types of cancer such as biliary tract cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. A joint trial with the Mayo Clinic unveils that epithelial TIL demonstrated the highest ability to distinguish between MMR-D (Mismatch repair deficiency) and MMR-P (Mismatch repair proficiency) tumors in colon cancer.

The post-hoc exploratory analysis results of three clinical trials utilizing Lunit SCOPE IO in Italy and France are also set to be showcased. In another study, HER2 (human epidermal growth factor receptor-2) scoring in biliary tract cancer was evaluated using Lunit SCOPE HER2. The analysis showed a substantial concordance of 75.3% between AI and human pathologists' assessments.

Another study aimed to predict multiple druggable mutations in non-small cell lung cancer (NSCLC) based on AI analysis of H&E images. More than 3,000 NSCLC samples were used as training data to develop an AI-powered predictive model. In validation in an independent dataset, the model showed robust performance in predicting six types of mutations (EGFR-mt, KRAS-mt, ALK-tr, ROS1-tr, RET-tr, MET-ex).

Following the results, it is expected that the newly developed AI genotype predictor, available for multiple genotypes in non-small cell lungcancer, holds immense potential for widespread adoption by clinicians and pharmaceutical industry leaders globally.